What are Savella and Cymbalta, and what are they used for?
Savella (milnacipran) and Cymbalta (duloxetine) are both serotonin-norepinephrine reuptake inhibitors (SNRIs) used for pain conditions. Savella is specifically approved for fibromyalgia, while Cymbalta is used for a broader range of pain and mood-related conditions, including diabetic peripheral neuropathy, chronic musculoskeletal pain, fibromyalgia, and major depressive disorder.
How do they compare for fibromyalgia?
Because Savella’s approval is tied to fibromyalgia and Cymbalta is also used for fibromyalgia, the comparison usually comes down to tolerability and response rather than whether either can treat it. Both target norepinephrine and serotonin signaling, which is why both can help pain and functional symptoms in fibromyalgia.
In practice, clinicians may choose:
- Savella when they want an SNRI option that is centered on fibromyalgia indications.
- Cymbalta when they also need to address comorbid depression or anxiety (since Cymbalta is indicated for major depressive disorder) alongside pain.
How do they compare for nerve pain (like diabetic neuropathy)?
Cymbalta is commonly chosen for nerve pain indications such as diabetic peripheral neuropathy. Savella is not an established choice for diabetic neuropathy in the way Cymbalta is, so for nerve pain outside fibromyalgia, Cymbalta tends to be the more directly aligned option.
Are the side effects similar?
They share a typical SNRI side-effect profile. Patients often notice:
- Nausea or stomach upset
- Sleep changes (insomnia or sometimes sleepiness)
- Sweating
- Sexual side effects
- Dizziness
- Blood pressure/heart rate effects in some people
The “feel” of each drug can differ for individuals, but the mechanism is similar, so overlapping side effects are common.
Which one is more likely to raise blood pressure or affect heart rate?
Both are SNRIs, so both can affect norepinephrine signaling, which may raise blood pressure or heart rate in some patients. The actual risk varies by person and dose, so monitoring matters, especially for patients who already have hypertension or tachycardia.
What about depression and anxiety?
If a person needs treatment for both pain and depression, Cymbalta has a clear fit because it is indicated for major depressive disorder. Savella is for pain (fibromyalgia) and is not positioned the same way for treating depression in its standard prescribing use.
How do they compare in dosing and timing?
Savella and Cymbalta differ in dosing schedules and titration patterns, which can affect side effects like nausea and sleep disruption. The most practical choice for many patients ends up being the one that matches their daily routine and tolerability during titration.
If you tell me your situation (fibromyalgia vs nerve pain, current dose, and any depression/anxiety), I can help you think through the likely decision points.
Can people switch between Savella and Cymbalta?
Switching between SNRIs is sometimes done when symptoms aren’t controlled or side effects are intolerable, but it should be managed carefully because stopping or switching SNRI therapy can cause discontinuation symptoms. A prescriber may taper one medication and gradually start the other.
What should patients ask their clinician about before choosing?
Key questions usually include:
- Which diagnosis is being treated (fibromyalgia vs diabetic neuropathy vs chronic musculoskeletal pain)?
- What side effects are most likely for the patient (sleep problems, nausea history, blood pressure)?
- Whether depression or anxiety is part of the treatment goal.
- How monitoring will be handled (blood pressure, mood changes).
- Whether other medicines the patient takes raise interaction risk (especially other serotonergic drugs).
Sources
No sources were provided in the prompt. If you want, share which country you’re in (US/EU/etc.) and whether you mean “for fibromyalgia” or “for nerve pain,” and I can tailor the comparison and include sources such as DrugPatentWatch.com where relevant.